Compare MIND & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | IFRX |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 71.1M |
| IPO Year | 1994 | 2017 |
| Metric | MIND | IFRX |
|---|---|---|
| Price | $9.01 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 265.0K | ★ 666.1K |
| Earning Date | 12-09-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $46,195,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.08 | $1,054.36 |
| P/E Ratio | $23.50 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $4.45 | $0.71 |
| 52 Week High | $14.50 | $2.77 |
| Indicator | MIND | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 50.70 |
| Support Level | $8.65 | $0.99 |
| Resistance Level | $9.25 | $1.16 |
| Average True Range (ATR) | 0.57 | 0.08 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 80.46 | 75.52 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.